NEW YORK (GenomeWeb) – The US Food and Drug Administration said on Tuesday that it has granted the first CLIA waiver to a nucleic acid-based flu diagnostic test, the Alere i Influenza A&B, allowing it to be used in a wider variety of healthcare settings.

Alere's test had previously been available for use only in certain laboratories. With the CLIA waiver, it can be distributed to non-traditional laboratory sites, including doctors' offices, emergency rooms, health department clinics, and other healthcare facilities, the FDA said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.